A CPhI report suggests that the pharma industry should be careful not to outsource to lower labor-cost countries rather than investing in manufacturing technology and innovation.
At CPhI Worldwide 2015 (Oct. 13–15, Madrid), CPhI Worldwide released part 3 of its annual report, which includes a Pharma Insights report by Prabir K. Basu, president of Pharma Manufacturing, OPEX and cGMP consultant, titled, "Innovation-can Pharmaceutical Manufacturing learn from the lessons in Auto Manufacturing in the US?" Basu suggests that pharmaceutical manufacturing in the US and Western Europe today has several characteristics in common with the US auto industry, which led to that industry's financial crisis in 2008. These include:
Although pharma has obtained high regulatory and compliance standards, "the current trend is that pharmaceutical manufacturing is gradually being outsourced to countries with lower labor cost without due consideration of regulatory standards in those countries, which have far less cGMP and regulatory history and experience," said Basu in the report. Quality cultures cannot be achieved overnight, but typically evolved over time, he warned. "Any experienced pharmaceutical manufacturing expert will agree that it is difficult to maintain low cost while investing in compliance...Quality is not cheap," added Basu. He warned that as products are outsourced to facilities in India and China, it is likely that these facilities are inheriting old processes with poor performance records, which creates quality risks.
Just as Japanese automakers obtained higher quality and greater success than US automakers by applying quality principles such as Deming's statistical process control, the pharmaceutical industry should take approaches such as quality by design, process analytical technology, and quality metrics, with greater investment in fundamental science and engineering to develop more cost-effective manufacturing processes, concluded Basu.
Source: CPhI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.